Dimerix (DXB) investor relations material

Strategic focus and pipeline highlights

• Advancing therapies for kidney diseases with significant unmet clinical needs, focusing on FSGS and acute kidney injury.

• DMX-200 completed Phase 3 recruitment for FSGS, with strong statistical power and orphan drug benefits in key markets.

• DMX-652, a Phase 2-ready asset for acute kidney injury, leverages unique mitochondrial targets and addresses a large, growing market.

• Both assets share renal expertise, infrastructure, and offer diversified growth and risk profiles.

Clinical development and trial progress

• DMX-200 Phase 3 trial for FSGS completed recruitment, with interim analysis showing positive proteinuria endpoint results.

• Over 90% of eligible patients entered the open-label extension, indicating strong engagement.

• DMX-652 Phase 2 trial will enroll 160 high-risk cardiac surgery patients, with primary endpoint of AKI incidence by day 7.

• Both programs have clear, staged value inflection points through 2028, including regulatory submissions and readouts.

Commercial partnerships and revenue potential

• Five commercial partners secured across major global territories, sharing development and commercialization risk.

• Up to $1.9 billion in total milestone payments and royalties possible from DMX-200 partnerships.

• Upfront and pre-launch payments total A$318 million, with significant post-launch milestone potential.

• Partners include BioMarin, Everest Medicines, Advanz, Fuso, and Taiba, each with tailored regional terms.